Effectiveness of biologic switching in a real-life, Belgian severe asthma cohort.
Journal
Immunity, inflammation and disease
ISSN: 2050-4527
Titre abrégé: Immun Inflamm Dis
Pays: England
ID NLM: 101635460
Informations de publication
Date de publication:
Oct 2024
Oct 2024
Historique:
revised:
28
08
2024
received:
03
06
2024
accepted:
04
09
2024
medline:
8
10
2024
pubmed:
8
10
2024
entrez:
8
10
2024
Statut:
ppublish
Résumé
In this observational study, we show that switching biologics in severe asthma results in a high proportion of controlled patients.
Substances chimiques
Anti-Asthmatic Agents
0
Biological Products
0
Types de publication
Observational Study
Letter
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e70023Informations de copyright
© 2024 The Author(s). Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.
Références
Eger K, Kroes JA, Ten Brinke A, Bel EH. Long‐term therapy response to anti‐IL‐5 biologics in severe asthma‐A real‐life evaluation. J Aller Clin Immunol. 2021;9(3):1194‐1200.
Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343‐373.
Matsumoto‐Sasaki M, Simizu K, Suzuki M, et al. Clinical characteristics of patients and factors associated with switching biologics in asthma. J Asthma Aller. 2022;15:187‐195.
Menzies‐Gow AN, McBrien C, Unni B, et al. Real world biologic use and switch patterns in severe asthma: data from the international severe asthma registry and the US CHRONICLE study. J Asthma Aller. 2022;15:63‐78.
Numata T, Araya J, Miyagawa H, et al. Effectiveness of switching biologics for severe asthma patients in Japan: a single‐center retrospective study. J Asthma Aller. 2021;14:609‐618.
Chapman KR, Albers FC, Chipps B, et al. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma. Allergy. 2019;74(9):1716‐1726.
Drick N, Milger K, Seeliger B, et al. Switch from IL‐5 to IL‐5‐Receptor alpha antibody treatment in severe eosinophilic asthma. J Asthma Allergy. 2020;13:605‐614.
Mümmler C, Munker D, Barnikel M, et al. Dupilumab improves asthma control and lung function in patients with insufficient outcome during previous antibody therapy. J Aller Clin Immunol. 2021;9(3):1177‐1185.e4.